Myelodysplastic Syndrome Market Size and Share Infographics
Myelodysplastic Syndrome Market

Myelodysplastic Syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow.


Some of the major symptoms of Myelodysplastic Syndrome include fatigue, shortness of breath, unusual paleness, easy or unusual bruising or bleeding, pinpoint-sized red spots just beneath the skin, and frequent infections. Genetic Syndromes, familial MDS, gender, and age, are some of the major risk factors for Myelodysplastic Syndrome.


Myelodysplastic Syndrome Epidemiology Insights Observed in 2020

  • The incident population of Myelodysplastic Syndrome in 7MM was found to be 41,586
  • The incident cases of Myelodysplastic Syndrome in the US were observed to be 20,428
  • The incident cases of Myelodysplastic Syndrome in Germany were estimated to be 4,515. While France, the UK, and Spain had 4,371, 3,302, and 2,010 cases respectively. 
  • Japan had 3,909 cases of Myelodysplastic Syndrome


Myelodysplastic Syndrome Epidemiology Segmentation in the 7MM for the Study Period 2018-30

  • Total incident population of Myelodysplastic Syndrome
  • Age-specific incident population of Myelodysplastic Syndrome
  • Subtype-specific incident population of Myelodysplastic Syndrome
  • Risk-specific incident population of Myelodysplastic Syndrome
  • Mutation-specific incident population of Myelodysplastic Syndrome


Myelodysplastic Syndrome Market Insight

The Myelodysplastic Syndrome market size in the 7MM was found to be USD 1,924 million in 2020.


Myelodysplastic Syndrome Market Drivers

  • Robust pipeline activity
  • Potential of upcoming therapies
  • Development of therapies for the second-line setting
  • Increasing awareness programs


Myelodysplastic Syndrome Market Barriers

  • Lack of treatment pattern studies in the 7MM
  • Underdiagnosis of MDS
  • The high-cost burden of MDS treatment
  • Progression of patients toward AML


Myelodysplastic Syndrome Emerging Therapies

The emerging drugs in the Myelodysplastic Syndrome market are

  • Roxadustat
  • Venclexta (Venetoclax) + Azacitidine
  • Magrolimab ± Azacitidine
  • Sabatolimab + Azacitidine
  • SY-1425 + Azacitidine
  • Pevonedistat ± Azacitidine
  • Glasdegib + Azacitidine/Cytarabine
  • Imetelstat
  • Eltanexor (ATG 016; KPT-8602)
  • Bemcentinib
  • Enasidenib
  • CPX-351
  • Eprenetapopt (APR-246)
  • Fludarabine + Busulfan ± Clofarabine
  • Treosulfan ± fludarabine

And many more.


Myelodysplastic Syndrome Market Prominent Players

The key companies in the Myelodysplastic Syndrome market are

  • Fibrogen
  • AbbVie
  • Gilead Sciences
  • Novartis
  • Syros Pharmaceuticals
  • Takeda
  • Pfizer
  • Geron Corporation
  • Karyopharm Therapeutics/Antengene Corporation
  • BerGenBio ASA
  • Bristol Myers Squibb
  • Jazz Pharmaceuticals
  • Aprea Therapeutics
  • Sanofi
  • Medac

And many others